Introduction: This paper analyses the UK’s decision not to utilise depot naltrexone for treating substance use disorder (SUD) by examining the pharmacological properties of naltrexone and its impact on SUD. This paper also evaluates various strategies other nations employ to combat SUD, exploring alternative approaches the UK can use to support these patients.
Aim: To explore why naltrexone depot is not used in the UK and alternative treatment strategies for SUD.
Objectives: This project aims to understand healthcare professionals’ views on current SUD programs, explore the potential of alternative approaches like the Russian and American models, and evaluate the benefits and drawbacks of using naltrexone depot. Methodology: This project interviewed healthcare professionals using a set of predetermined questions to gather qualitative data on the impact of SUD on society, available treatment options, and the potential effectiveness of using a naltrexone depot. The data was collected and underwent thematic analysis to identify key themes and insights, providing a comprehensive understanding.
Results: Thematic analysis identified a relationship between the treatment choice and funding towards SUD, which also impacts service access and psychosocial support. Despite the current efforts to change this narrative, there remains a pre-existing stigma towards these clients and their lifestyles. Current programs are also unsustainable, and changes must be made, such as a holistic, multi-disciplinary team (MDT) approach to support the use of depot naltrexone.
Conclusion: For depot naltrexone to be used effectively in the UK, there needs to be a new holistic approach to treatment with sufficient funding. However, more research is necessary to fully understand its effectiveness and safety, as current knowledge is limited.
PLEASE NOTE: You must be a member of the University of Lincoln to be able to view this dissertation. Please log in here.